Results 1 to 10 of about 67,560 (281)

Determination of Phosphodiesterase Type-5 Inhibitors (PDE-5) in Dietary Supplements [PDF]

open access: yesMolecules, 2023
This study proposed a high-performance thin-layer chromatography (HPTLC) screening method to detect phosphodiesterase 5 (PDE-5) inhibitors as possible adulterant agents in various dietary supplements.
Oana Ramona Cătălina Gheorghiu   +7 more
doaj   +4 more sources

Phosphodiesterase Type 5 Inhibitors Greatly Affect Physicochemical Properties of Model Lipid Membranes [PDF]

open access: yesMembranes, 2021
Although phosphodiesterase type 5 inhibitors are widely used and well-studied drugs, the potential benefits of their application in the treatment of various diseases and new drug delivery systems, including liposome forms, are still being discussed.
Anastasiia A. Zakharova   +2 more
doaj   +2 more sources

Phosphodiesterase Type 5 Inhibitors, Sport and Doping [PDF]

open access: yesCurrent Sports Medicine Reports, 2017
Phosphodiesterase type 5 inhibitors (PDE5i) (e.g., sildenafil, tadalafil, vardenafil, and avanafil) are drugs commonly used to treat erectile dysfunction, pulmonary arterial hypertension, and benign prostatic hyperplasia.
Borrione, Paolo   +8 more
core   +5 more sources

Phosphodiesterase Type 5 Inhibitors and Visual Side Effects: A Narrative Review [PDF]

open access: yesJournal of Ophthalmic & Vision Research, 2021
Phosphodiesterase type 5 inhibitors such as sildenafil citrate and tadalafil are well known for the treatment of erectile dysfunction. However, their use in the presence of pulmonary hypertension can cause ophthalmologic side effects, including non ...
Francisco Barroso   +2 more
doaj   +2 more sources

UPLC-MS/MS-Based Target Screening of 90 Phosphodiesterase Type 5 Inhibitors in 5 Dietary Supplements [PDF]

open access: yesMolecules
The aim of individuals consuming health supplements is to attain a robust state through nutritional regulation. However, some unscrupulous manufacturers, motivated by profit, fraudulently incorporate drugs or unauthorized components with therapeutic ...
Shaoming Jin   +6 more
doaj   +2 more sources

A review of phosphodiesterase type 5 inhibitors [PDF]

open access: yesSouth African Family Practice, 2014
Currently, three phosphodiesterase type 5 (PDE5) inhibitors are available for clinical use in South Africa; sildenafil, vardenafil and tadalafil. The PDE inhibitors are used in males to treat erectile dysfunction.
N. Schellack, A. Agoro
doaj   +3 more sources

Phosphodiesterase type 5 inhibitors and erectile dysfunction [PDF]

open access: yesSouth African Family Practice, 2010
Erectile dysfunction (ED) affects millions of men globally and may adversely affect his, and potentially his partners’, quality of life. The introduction, a decade ago, of the phosphodiesterase type 5- (PDE5-) inhibitors has revolutionised the management
Catherine Whittaker
doaj   +2 more sources

Effect of phosphodiesterase type 5 inhibitors on sperm motility and acrosome reaction: An in vitro study [PDF]

open access: yesInvestigative and Clinical Urology, 2021
Purpose: Phosphodiesterase type 5 (PDE5) inhibitors are effective treatments for erectile dysfunction, and several recent studies have reported positive effects of PDE5 inhibitors on semen parameters as well. However, the data are still controversial. We
Seung-Hun Song   +8 more
doaj   +3 more sources

Effects of phosphodiesterase type 5 inhibitors on choroid and ocular vasculature: a literature review [PDF]

open access: yesInternational Journal of Retina and Vitreous, 2020
To provide information on the effects of phosphodiesterase type 5 (PDE5) inhibitors on choroidal vessels and central serous chorioretinopathy (CSC) and possible implications for development of exudative age-related macular degeneration (AMD).
Natasha Ferreira Santos da Cruz   +7 more
doaj   +2 more sources

Medication adherence, hospitalization, and healthcare resource utilization and costs in patients with pulmonary arterial hypertension treated with endothelin receptor antagonists or phosphodiesterase type-5 inhibitors [PDF]

open access: yesPulmonary Circulation, 2020
Adherence to therapy for pulmonary arterial hypertension is essential to optimize patient outcomes, but data on real-world adherence to different pulmonary arterial hypertension drug classes are limited.
Robert P. Frantz   +6 more
doaj   +2 more sources

Home - About - Disclaimer - Privacy